Fulcrum Therapeutics, Inc. (FULC): Shareholders' Equity
$349.00M
As of 2025-12-31
$310.70M
As of 2026-06-30
+20.6%
3-year compound annual growth
+29.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $349.00M | +43.6% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $243.03M | +3.3% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $235.19M | +18.2% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $198.94M | -6.0% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $211.54M | +122.2% | 2023-06-26, Balance as of period end |
| 2020-12-31 | $95.18M | +9.2% | 2023-06-26, Balance as of period end |
| 2019-12-31 | $87.15M | n/m | 2023-06-23, Balance as of period end |
| 2018-12-31 | -$63.67M | n/a | 2020-03-05, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | 2025-12-31 | $349.00M | +43.6% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare FULC, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗